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Abstract
Staphylococcus aureus vaccines based on bacterins surrounded by slime, surface polysaccharides
coupled to protein carriers and polysaccharides embedded in liposomes administered together with
non-biofilm bacterins confer protection against mastitis. However, it remains unknown whether
protective antibodies are directed to slime-associated known exopolysaccharides and could be
produced in the absence of bacterin immunizations. Here, a sheep mastitis vaccination study was
carried out using bacterins, crude bacterial extracts or a purified exopolysaccharide from biofilm
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bacteria delivered in different vehicles. This polysaccharide reacted specifically with antibodies to
poly-N-acetyl-β-1,6-glucosamine (PNAG) and not with antibodies to other capsular antigens or
bacterial components. Following intra-mammary challenge with biofilm-producing bacteria,
antibody production against the polysaccharide, milk bacterial counts and mastitis lesions were
determined. Bacterins from strong biofilm-producing bacteria triggered the highest production of
antibodies to PNAG and conferred the highest protection against infection and mastitis, compared
with weak biofilm-producing bacteria and non-cellular inocula. Thus, bacterins from strong
biofilm bacteria, rather than purified polysaccharide, are proposed as a cost-efficient vaccination
against S. aureus ruminant mastitis.
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1. Introduction
Staphylococcus aureus adhesins are involved in the establishment of infection through early
attachment to host tissues [1]. A second step in virulence results in intercellular adhesion
among bacterial cells and subsequent development of a biofilm, leading to chronic infections
and bacterial resistance to phagocytosis [2,3,4]. A major constituent of the staphylococcal
biofilm matrix is the poly-N-acetyl β-1,6 glucosamine surface polysaccharide, synthesized
by proteins encoded by the intercellular adhesion ica operon [5]. This homopolymer has
been named PIA, polysaccharide intercellular adhesin, in S. epidermidis [6] and PNAG in S.
aureus [7]. Another, though less frequent biofilm constituent among mastitis isolates is the
Bap protein [8]. In S. aureus studies, PNAG exopolysaccharide conjugated to diphtheria
toxin has been proposed as a vaccine candidate in laboratory animals against systemic
infection [9]. The results showed a protective effect [10]. This conjugate-vaccine strategy
may be useful in humans but may not be cost-efficient for staphylococcal ruminant mastitis.
Different vaccination strategies involving surface polysaccharides have been evaluated for
efficacy against staphylococcal mastitis in ruminants, encompassing inactivated bacteria and
toxoids [11]; bacteria surrounded by a mucous substance (likely a biofilm matrix) termed a
pseudo-capsule [12] or slime [13]; capsular polysaccharide (CP), types CP5, CP8 and
CP336 linked to protein carriers [14,15,16]; CP5 co-entrapped in liposomes with alpha-toxin
[17]; and a mixture of slime in liposomes, toxoid and different inactivated bacteria [18].
Several field trials with these and other vaccines including bacterin-toxoid [19,20,21], crude
extracts of encapsulated bacteria in aluminum hydroxide [22,23], have revealed a significant
degree of protection against mastitis. One of the main goals in vaccination against mastitis is
to obtain reduced inflammation at the site of injection, high efficiency against disease, a
cost-efficient bacterial inoculum and an immunological parameter that could help to predict
the success of vaccination.
Data on the specific role of biofilm matrix polysaccharides in the development of a
protective immune response against S. aureus mastitis are limited. Here, we used different
vaccine preparations and performed a comparative immunization-challenge study against S.
aureus mastitis in sheep. Immunization was done with: a) cell-free surface polysaccharide
(PNAG), purified or in the form of cell extracts, in different vehicles (liposomes,
microparticles or aluminum hydroxide); b) S. aureus unbound cells (not within biofilm) in
adjuvant (aluminum hydroxide); or c) S. aureus cells embedded in their biofilm matrix in
different adjuvants. This study demonstrated that vaccination with whole bacterial cells
surrounded by their own biofilm matrix containing PNAG conferred protection against S.
aureus infection and mastitis. This protection was related to the level of antibodies to S.
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aureus PNAG and to the degree of biofilm formation and PNAG production of the
immunizing strain, and was independent of the adjuvant and CP type of the challenge strain.
This information may be relevant to mastitis vaccine design and identification of an immune
correlate associated with protection against mastitis.
2. Materials and Methods
2.1. Bacterial cultures for enrichment of adherent bacteria
Four S. aureus isolates of different CP types were used in the immunization study (Table 1).
Originally, they all had a moderate-to-weak biofilm production capacity, being assigned to
the group of “weak biofilm phenotype” bacteria, even though they all were ica-positive. To
enhance biofilm production, repeated bacterial cultures were grown at 37°C in Tryptic Soy
Broth (TSB) or Tryptic Soy Agar (TSA) supplemented with glucose (2 %, w/v) (TSA-G,
Panreac). At the end of the process, the adherent bacteria were able to produce rough
colonies on Congo red agar (TSA-G supplemented with 0.08 % Congo Red; [24]) and
produced a “strong biofilm phenotype” [8,24], as assessed by polystyrene adherence tests
[25] (see below).
2.2. Hyperimmune serum
Hyperimmune serum was produced in Rasa Aragonesa adult sheep for detection of PNAG.
For this, intramuscular immunizations were done with ATCC29213 strong biofilm
phenotype bacteria embedded in biofilm and adjuvant (1010 heat-killed bacteria emulsified
in incomplete Freund adjuvant) [26]. Some serum aliquots were absorbed with S. aureus
Newman (weak biofilm phenotype, CP5 strain) to remove antibodies to CP5 and common
cell surface components. This absorption had a minimal effect on removal of PNAG
antibodies. Alternatively, serum was absorbed with non-encapsulated (CP-negative) bacteria
(S. aureus JL252, a weak biofilm phenotype strain derived from the CP8-Becker strain but
genetically modified so as to not express CP; kindly provided by J.C. Lee, Brigham and
Women’s Hospital, Harvard Medical School). The efficiency of absorptions was verified by
double agar gel immunodiffusion (AGID) and immunoelectrophoresis (IEP) assays.
2.3. Preparation of crude bacterial extracts
Crude bacterial extracts were prepared [27]. Briefly, 500 µl of an overnight culture (18 h) of
each isolate were spread on a TSA-G plate which was incubated for 24 h at 37°C. Bacteria
were autoclaved at 121°C for 60 min. Cells and cell debris were removed by centrifugation
(10,000 × g for 60 min). The pellet was diluted in PBS and the autoclaving and
centrifugation steps were repeated. The supernatants were pooled, dialyzed against
deionized water for 48 h at 4°C, passed through 0.22 µm filters and lyophilized.
2.4. Agar gel and dot blot serologic tests
AGID test was used as previously described [28,29] and precipitin lines were examined at
24 and 48 h. For IEP, antigens from the bacterial extracts were separated by electrophoresis
in 1 % agarose gels (pH 8.3). Purified PNAG and the antibody to deacetylated PNAG
(dPNAG) were used as antigen positive controls [30]. Following electrophoresis, the
antiserum (a hyperimmune serum against S. aureus ATCC29213 of strong biofilm
phenotype or anti-PNAG antibodies) diffusion was allowed for 24 h. The precipitin lines in
IEP disappeared upon treatment of crude extracts with sodium metaperiodate (Fluka) due to
carbohydrate oxidation of the antigen [31] (not shown). The PNAG immunological
specificity of the polysaccharide preparation was further analyzed by dot-blot [5] using
antibodies previously described [7].
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2.5. PNAG purification
PNAG was purified according to established procedures [10]. Alternatively, to separate it
from CP, crude extract was fractionated on a HiLoad ™ 16/10 Q Sepharose column fast
flow anion exchange chromatography (Pharmacia), using 0.02 M HCl-Tris buffer (pH 8).
Fractions were concentrated and the presence of PNAG detected by IEP using antiserum
against strong biofilm phenotype bacteria. PNAG-containing fractions were pooled, treated
overnight with proteinase K (1 mg/mL; 37°C), dialyzed against distilled water and
lyophilized.
2.6. Quantification of PNAG by inhibition ELISA and indirect ELISA
PNAG was quantified in bacterial extracts by an ELISA inhibition method using anti-PNAG
antiserum (described in section 2.2) absorbed with S. aureus strain Newman (being CP5 and
a weak biofilm phenotype strain), purified PNAG-coated wells and protein G conjugated
with peroxidase. Data (sample dilution producing 50% inhibition) were analyzed with a
linearity test using the Logit and Log transformations [32]. The indirect ELISA was carried
out like the inhibition ELISA, except that 100 µl of serum from hyperimmunized animals
(Section 2.5) was used as primary antibody.
2.7. Vaccination, challenge and analysis of sheep
To determine the immunogenicity and efficacy against infection, a total of 81 healthy
pregnant Rasa Aragonesa sheep lacking detectable serum antibodies against Staphylococcus
were randomly allotted into ten experimental groups. Nine of these groups (n=65) were
immunized and challenged (Section 2.7.1). After challenge, animals were analyzed
according to immunological, bacteriological and pathological criteria (Section 2.7.2). An
additional (control) group (n=16) of non-vaccinated sheep was examined, challenged,
examined and maintained under the same experimental conditions. Animal handling and
experimental procedures were in accordance with European directives (DOCE 86/609/EEC),
and approved and supervised by the Ethical Committee of the Institution.
2.7.1. Sheep Immunization and challenge—Different immunization approaches were
undertaken, as specified in Table 2. Bacterins containing bacteria embedded in PNAG
containing matrix, anion-exchange purified PNAG or crude extracts containing PNAG were
used. For bacterin inocula (bacteria surrounded by a PNAG containing matrix), S. aureus
ATCC29213 or C104 were independently used. The capsular type of both bacterial isolates
was different from that of the challenge isolate S. aureus C195 (CP8), in order to ensure that
the effect of vaccination was not attributable to CP immune response. Bacterins containing
bacteria in strong biofilms (enriched for biofilm production) corresponded to Groups 1, 3 (S.
aureus ATCC29213) and 2 (S. aureus C104). Bacterins containing free (non-biofilm)
bacteria of a weak biofilm phenotype (not enriched for biofilm production) corresponded to
Groups 4 (S. aureus ATCC29213) and 5 (S. aureus C104) and were used for comparative
purposes. As adjuvants, four of these groups (1, 2, 4 and 5) received aluminum hydroxide,
and group 3 received a commercial adjuvant (Laboratorios HIPRA S.A.). Bacterium-free
PNAG (soluble antigen hereafter) was used as follows: a) purified and mixed with
liposomes and an E. coli bacterin (Laboratorios HIPRA S.A.) (Group 6); b) in the form of
crude extract mixed with liposomes (Group 7); c) purified and delivered in microparticles
(Group 8); or d) purified and mixed with liposomes (Group 9). Animals inoculated with PBS
were used as non-immunized controls.
Animals were immunized twice five weeks apart, carrying out the first immunization at 3.5
months of pregnancy. Groups 1, 2, 4, 5, 7 and 9 were immunized intramuscularly, like in our
previous study [18], and groups 3, 6 and 8 were immunized subcutaneously, following
recommendations for use of the specific delivery systems and the non-staphylococcal part of
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the inoculum. According to the intra-group variance expected in the parameters analysed,
the number of sheep used for immunization or control groups ranged from 5 to 16 sheep (i.e.
n=8 in groups 1–5; n=5 in groups 6–8; n=10 in group 9; and n=16 in control group).
Preparations of bacterin inocula (groups 1–5) consisted of 1010 bacteria per inoculum, per
bacterial isolate, obtained as indicated below, using 1 mL of aluminum hydroxide (3 ‰) or 1
mL of commercial adjuvant (from Laboratorios HIPRA S.A.) as adjuvants and S. aureus
ATCC29213 (CP5) or C104 (CP non-typable) as specified in Table 2. For cell-free PNAG
inocula, 2 mg of PNAG (obtained by ion exchange chromatography) were used in all the
sheep groups. This amount of PNAG was inoculated in one sheep group in the form of crude
bacterial extracts (15 mg) from strong biofilm phenotype S. aureus ATCC29213 (CP5) and
76 (CP8), that were mixed with liposomes in a final mixture of 30 mg (group 7). Liposomes
were produced as described previously [33]. Alternatively, purified PNAG (2 mg) was used:
a) mixed 1:1 (vol/vol) with liposomes (group 9); b) mixed 1:1 (vol/vol) with liposomes and
also including in the inoculum 1 mL of an Escherichia coli bacterin (Laboratorios HIPRA
S.A.) (group 6); or c) included in microparticles prepared at the Galenic Center of the
University of Navarra (group 8). For the preparation of antigen-loaded microparticles, the
following materials were used: Poly(ε-caprolactone) (PEC; Mw 42,500) from Aldrich-
Chemical Company (USA). Poly(D,L-lactide-co-glycolide) with a monomer ratio of 50:50
(PLGA 502; Resomer® RG 502) from Boehringer Ingelheim, Germany. PNAG-loaded
microparticles were prepared (size close to 2.00 µm) using Total Recirculation One-
Machine System (TROMS) [34]. The quantification of NaOH hydrolysed antigen was
carried out by an indirect ELISA. Encapsulation efficiency for PEC and PLGA 502
microparticles was 96.02 % and 98.84 %, respectively.
Two weeks after the booster immunization (about four days after parturition), each animal
was challenged in each mammary gland (gland duct inoculation) with 103 bacteria of strain
S. aureus C195 (ica+ and bap-, CP8) expressing a strong biofilm phenotype.
2.7.2. Immunological, bacteriological and clinical determinations in sheep—
Sera were collected just before immunization, then, weekly after priming and daily during
nine days after challenge, for determining the level of antibodies against PNAG by indirect
ELISA. Collection of milk samples and examination (color, texture, temperature, pain, size
and lameness) of mammary gland was also performed daily (for nine days) after challenge.
For bacteriological purposes, the number of viable CFU per mL of milk was determined by
plating 25 µL of each eight ten-fold dilution onto TSA plates, by triplicate. After logarithmic
transformation, results were expressed as mean ± standard error (s.e.). Clinical examination
allowed the establishment of four categories according to severity of mastitis: good (G,
healthy or with a very mild mastitis), medium (M, with moderate mastitis), damaged (D,
with strong mastitis), very damaged (VD, with highly severe mastitis). Often, animals
showed a progression of mastitis and were classified accordingly as either G/M (initial post-
challenge period with a good health status but ending with moderate mammary lesions) or
M/D (initial post-challenge period with an intermediate health status but ending with serious
mammary lesions). The establishment of these 6 categories allowed the classification of
animals into three major types, according to the health status and lesion degrees, which
facilitated the statistical analysis and its interpretation: Type I (G + G/M), Type II (M + M/
D) and Type III (D + VD). When an animal died from mastitis within the 9 day post-
challenge period, the log CFU/mL recorded at death was fixed and used thereafter for this
animal till the end of the experimental period.
2.8. Statistical analysis
A Chi square test was used to compare the proportion of animals with lesions between the
vaccinated groups and the control group. A repeated-measure analysis of variance was
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applied for antibody titer as well as bacterial cell count statistical comparisons. A Kaplan-
Meier survival analysis was applied to generate a Cumulative Survival Plot. Statistical
comparisons between survival curves were performed by the Log-Rank test (once verified
the parallelism of the survival curves), using the StatView® program for Windows (version
5.0, SAS® Institute Inc.).
3. Results
3.1. PNAG/Biofilm production by the isolates used in immunization and challenge
According to serum absorption and the different serological assays (AGID, 1D-and 2D IEP,
dot blot, ELISA), PNAG was the only molecular species in the extracellular matrix obtained
distinguishing strong from weak biofilm phenotypes in each isolate and it had the same
antigenic specificity among different isolates. A competition ELISA that quantified PNAG
in the samples used for immunization indicated that the proportion of PNAG (as detected by
OD A405) in the bacterial crude extract was about 1:16 (w/w) among the strong biofilm
phenotype isolates used for crude bacterial extract immunization, information that was taken
into account for preparation of cell-free inocula used in immunization. Biofilm formation
(determined by late adherence tests) and levels of PNAG production (both highly associated
in previous studies and this work, P<0.01; R = 0.86) were the highest in S. aureus
ATCC29213, followed by other strong biofilm phenotype isolates (S. aureus C104, 76 and
C195). Three of these strong biofilm phenotype isolates (S. aureus ATCC29213, C104, and
76) and the corresponding weak phenotype controls (S. aureus ATCC29213 and C104) with
very limited PNAG production, were used for immunization and the remaining isolate
(C195 of strong biofilm phenotype) for challenge.
3.2. Antibody response
The antibody response to immunization in the different study groups (Table 2) was
determined before challenge using a PNAG-based ELISA and categorized according to OD
values obtained (OD405). Among the bacterin-immunized groups (Fig. 1a), the highest
(P<0.0001) antibody response was found in Group 1, the group immunized with the
strongest biofilm phenotype bacteria inoculated along with aluminum hydroxide (alum),
with a mean ELISA OD value ≥0.8 after the first immunization. A lower but still detectable
antibody production was found in the groups immunized with the same bacteria using a
commercial adjuvant (Group 3) and with other strong biofilm phenotype bacteria in alum
(Group 2) (P<0.0001 for differences between control and groups 2 or 3). Interestingly, only
the groups immunized with bacterin from the strongest biofilm phenotype bacteria (Groups
1, 2 and 3) maintained a mean OD value above 0.4 from week 1 to challenge. In contrast,
groups immunized with bacteria of a weak biofilm phenotype in alum (Groups 4 and 5) did
not produce a significant antibody response to PNAG.
The groups immunized with cell-free PNAG (Fig. 1b) showed a significant (P<0.0005)
antibody production compared with the unvaccinated control. This response was lower
(P<0.0001) compared with that of animals immunized with biofilm bacterins (Groups 1, 2
and 3, Fig. 1a), with the exception of Group 6, which maintained OD values in the range of
0.4–0.6. This group was inoculated with PNAG in liposomes (like Group 9, which had the
lowest antibody titer), but in the presence of an E. coli bacterin in the inoculum.
3.3. Bacterial cell counts and animal deaths
Bacterial cell counts in milk (CFU per mL) were determined for 9 days after challenge with
a heterologous biofilm producing strain (S. aureus C195, of strong biofilm phenotype).
Groups 1, 2 and 3 had a decreased bacterial cell count throughout the study period compared
with the remaining immunized (P<0.005) and control (P<0.0008) groups (Fig. 2a),
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indicating that immunization with strong biofilm phenotype bacteria conferred a significant
degree of protection. A reduced number of CFU in milk was observed also in Groups 6
(P<0.07) and 8 (P<0.0001) compared with the unvaccinated control group (Fig. 2b).
However, protection in both immunized groups was lower (P<0.005) than that observed in
Groups 1, 2 and 3. The remaining experimental groups were not protected (Groups 4, 5, 7,
and 9). Overall, these results indicate that increased PNAG antibody production in
immunized animals (Fig. 1) was associated with decreased bacterial counts after challenge
(Fig. 2).
None of the animals in the 5 groups inoculated with bacterins (Groups 1–5) died from
infection during the 9-day post-challenge period. In contrast, there were dead animals in the
4 groups immunized with purified PNAG or PNAG-containing crude extract (Groups 6–9).
Animals which died from mastitis had challenge bacterial counts in milk above 7 log CFU/
mL. Kaplan-Meier cumulative survival curves are shown in Fig. 3 for Groups 6–9. Although
there were no statistically significant differences in cumulative survival between these
groups, death rates were 20 % in Group 8 and about 40–50 % in the remaining Groups 6, 7,
9 and control.
3.4. Health status and mammary lesions
After observing no adverse reactions locally or systemically in any of the animals as a result
of the immunization, the relationship between the degree of mammary gland lesions and
antibody titers to PNAG was investigated. Results on mammary gland lesions observed 9
days post-challenge are summarized in Table 3. Mammary glands were classified into three
types according to lesions and health status: Type I, with no lesions or with very mild
lesions; Type II, with moderate or moderate-to-severe lesions; and Type III, with severe
lesions that lead to death in some cases. As shown in Table 3, control group animals
belonged to Types III (10) or II (6) but not I. None of the animals from the 5 groups
immunized with bacterins (Groups 1–5) presented Type III lesions. Animals from groups
immunized with cell-free antigens (Groups 6–9) had Type I, II or III lesions. Comparing
lesion Types (I, II and III) found in the vaccinated groups with respect to non-vaccinated
controls, the percentage of animals immunized with strong biofilm bacterins (Groups 1–3)
showed the mildest lesions (16 vs. 0 animals with Type I lesions, P<0.0005; and 0 vs. 10
animals with Type III lesions, P<0.0001). In contrast, most animals (7 out 16) vaccinated
with weak biofilm bacterins (Groups 4 and 5) had Type II lesions and, therefore, these
lesions were more frequent than in groups immunized with strong biofilm bacterins
(P<0.0001). In sheep immunized with cell-free antigens (Groups 6–9) a similar proportion
of animals with Type II and Type III lesions was found compared with the unvaccinated
control (P>0.05). However, Type I lesions in these vaccinated groups were more frequent
(P=0.014) than in controls, indicating a slightly protective effect conferred by cell-free
antigen immunization. When analyzed together, the two groups receiving cell-free antigens
entrapped in liposomes (Groups 7 and 9) showed a higher (P=0.024) number of Type II and
Type III lesions and lower (P=0.042) number of Type I lesions than the other cell-free
antigens immunized groups (Groups 6 and 8). Altogether, these results indicate that all the
immunized sheep exhibited some degree of protection against clinical mastitis, with the best
results in the groups immunized with the strong biofilm bacterins.
3.5. PNAG antibody levels and health status
When considering all the immunized animals involved in this study, an inverse association
was found between the antibody levels (Absorbance at 405 nm in ELISA) reached before
challenge and the bacterial counts in milk and lesions observed 9 days after challenge with
S. aureus C195 of strong biofilm phenotype. As shown in Table 4, a low antibody
production (OD < 0.31) upon immunization was associated with medium (106–107) - to -
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high (107) CFU of S. aureus per mL of milk, and medium (Type II) - to - severe (Type III)
mastitis post-challenge. The reverse situation was found when the antibody production
increased (OD > 1) being associated exclusively with a Type I healthy status. Overall, these
results indicate that immunization with strong biofilm bacterins triggered the highest PNAG
antibody levels upon immunization and conferred the highest protective effect, against
infection and disease after challenge.
The relationship between PNAG antibody levels and protection against fatal mastitis was
confirmed in the non-immunized (control) group after experimental challenge. As shown in
Fig. 4, only the animals that produced PNAG antibodies reaching an OD in ELISA of about
0.2 (or higher) and having also a clear progression of antibody production at day 7, 8 and 9
post-challenge survived at the end of the experimental period (9 days post-challenge). This
control group was composed of 16 sheep which did not have naturally occurring PNAG-
specific antibodies before challenge and only produced them after challenge. There were 4
additional sheep which had naturally occurring antibodies to PNAG before challenge, due to
natural infections, and were not included in the control or immunized groups. Thus, PNAG,
presumably expressed in vivo in natural or experimental infections, triggers the production
of naturally occurring IgG antibodies in sheep, as detected by ELISA.
4. Discussion
Previous studies have shown that immunization of ruminants either with inactivated biofilm
bacteria and toxoid [35,36] or with biofilm matrix exopolysaccharides (slime) in liposomes,
inoculated in the presence of toxoid and low-adherence inactivated bacteria [18] confer
protection against ruminant mastitis, helping to avoid production losses. Here we have found
that among ruminant isolates of S. aureus, the presence of PNAG is associated with a higher
late adherence and capacity to produce biofilm, as is found among human clinical isolates
[5,9]. Furthermore, antibodies to this polysaccharide were associated with resistance to
mastitis. In contrast with the heterogeneous CP types (mainly including CP5, CP8 and
CP336 [14,15]), all the strong biofilm phenotype isolates tested were, to our knowledge, of a
single PNAG serotype, whose specificity could not be further fractionated by serum
absorption (data not shown). This is important for vaccination purposes, because PNAG
may confer a broad-spectrum protection (within and across mammalian species) against the
different staphylococcal ica-dependent biofilms that lead to chronic infections.
Protection conferred by bacterins consisted of a significantly decreased bacterial cell count,
which is widely known to be associated with decreased somatic cell count and increased
milk production and quality, and diminished or absent mammary gland lesions. This
protection could not be explained by the effect of antibodies against CP antigens, since
immunization vs. challenge bacteria CP types differed.
In cell-free immunizations, the immune response could not be consistently enhanced by
including non cellular components in the immunization, for example crude extracts from an
additional isolate (Group 7) of the same capsular type as the challenge isolate. The reason
for this could most likely be that crude extract or purified polysaccharides (including PNAG
and CP) need to be linked to protein or presented in the context, for example, of a bacterial
cell for enabling linked-antigen recognition and the production of significant immune
responses. Consistent with this was the limited antibody production triggered by the cell-free
immunogens in the absence of bacterial cells. However, when PNAG soluble antigen was
mixed with inactivated E. coli cells, the immune response against PNAG was enhanced in
the surviving sheep (others died), likely because E. coli facilitated immune responses or
promoted an environment leading to enhanced antibody production. We have previously
induced an immunological response using a staphylococcal extracellular polysaccharidic
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component, referred to as slime, in liposomes in a vaccination strategy also involving
inactivated bacteria and toxoid [18]. Again, inactivated bacteria may have facilitated
enhanced recognition of the polysaccharide antigen. Consistent with this is the need of
coupling of capsular antigens of S. aureus to protein carriers [17,37] or their administration
as a bacterin [35,36] to trigger antibody production protective against mastitis (a bacterin
approach may be made readily accessible to livestock industry). Similarly, PNAG has been
coupled with protein carriers to immunize and protect against staphylococcal infections in
laboratory animals [10]. Interestingly, PNAG- specific antibodies that mediate opsonic
killing in these animals and in humans bind primarily to the non acetylated epitopes of this
antigen [38,39]. N-acetylation of ≥40% on PNAG will elicit primarily antibodies to the
poorly-protective epitopes. However, evidence for such level of PNAG N-acetylation was
not obtained for the purified PNAG used in this work (not shown). One of the reasons for an
increased titre of antibody to PNAG in group 7 (that received crude antigen with highly
acetylated native PNAG) compared with group 9 (immunized with purified PNAG) but a
similarly poor protection may be that, in group 7, antibodies were mainly produced to
acetylated PNAG and did not have good opsonic killing activity. Interestingly, native PNAG
surrounding bacteria do elicit antibodies conferring protection. Additional studies are needed
to address this aspect of PNAG vaccines. According to our previous study [39], there is a
preferential retention of the deacetylated form of the antigen on the cell surface. This
dPNAG form is able to trigger opsonic antibodies upon immunization and has been
proposed as a vaccine candidate, as the antibody produced against dPNAG favours
opsonophagocytosis and results in increased survival in a murine bacteraemia model. Most
likely, the protective antibodies formed in our present study using whole cells surrounded by
PNAG are expected to be against dPNAG and promote opsonophagocytosis, resulting in
protection against infection and mastitis.
Groups immunized with strong biofilm phenotype bacterins conferred the highest protection
and groups immunized with bacterins were the only ones that conferred protection against
severe disease or death (Type III mastitis) under the conditions studied. Aluminum
hydroxide enhanced antibody production in strong biofilm phenotype bacterins, compared
with other adjuvants tested. As expected, the bacterin that triggered the highest antibody
production and conferred the highest protection against mastitis was that of the isolate with
the highest capacity to produce biofilm and PNAG in this study (ATCC29213 of strong
biofilm phenotype) when administered with alum. Further studies to determine if the
immunity obtained against mastitis is long-lasting and how often should the immunization
be done are warranted.
Because PNAG antibody production was found in the majority of control animals after
challenge, it was difficult to separate the effect of immunization from that of infection and
antibody production in this period (data not shown). The production of PNAG antibodies in
control animals after challenge strongly suggests that PNAG is expressed by strong biofilm
bacteria in vivo during mammary gland experimental infections. Also, we found animals that
were excluded from this study because they had naturally occurring PNAG-specific
antibodies, presumably as a result of in vivo PNAG expression from a natural infection
[40,41]. This finding is relevant because it confirms the antigenicity of PNAG in natural
ruminant mastitis infections involving in ica+ isolates.
Possibly, as shown in other PNAG studies [10,38], PNAG-specific IgG antibodies opsonize
PNAG bacteria, favoring phagocytosis and leading to resistance to fatal disease. Both main
IgG subclasses, IgG1 and IgG2, may play an important role in sheep against mastitis: IgG1
is actively transported into the non-inflamed gland from serum to milk and binds
macrophages commonly present in this gland, whereas IgG2 is cytophilic for neutrophils,
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reaching high levels in serum in the course of infection and then being transferred from
serum to the inflamed gland through transudation [18].
The ovine strong biofilm phenotype isolates used in this work were ica-positive but reverted
to the weak biofilm phenotype if the selection pressure for adherence was discontinued upon
repeated subcultures. Stable strong biofilm phenotypes have been described (S. aureus strain
ISP479c; [42]). However, stable strong biofilm phenotypes such as that of the human isolate
S. aureus 15981, that for unknown reasons produces PNAG in a stable manner, have been
found only in a minority of ica-positive bacteria whose biofilm is ica-dependent [43]. This
work encourages the search for strains displaying this stable phenotype, as they could be
candidates for developing commercial staphylococcal vaccines delivered to ruminants in the
form of biofilm bacterin. We are currently analyzing whether regulators already identified as
important for biofilm formation in S. aureus, such as SarA [44,45], IcaR and TcaR [46,47]
and σB are involved in the stabilization of PNAG production.
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Fig. 1.
Production of antibodies (O.D., expressed as A405 mean ± standard error, s.e.) against
PNAG, as detected by ELISA. Immunization and booster were performed at weeks 0 and 5,
respectively, with S. aureus bacterins (a) or cell-free components (b). Control animals were
non-vaccinated sheep maintained under the same experimental conditions as the vaccinated
sheep. None of the animals had been submitted yet to challenge with S. aureus. The size of
ranged from 5 to 10 sheep (5 sheep in groups 6–8 and 10; 8 sheep in groups 1–5; and 10
sheep in group 9) immunized groups and was n = 16 in the unvaccinated control.
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Fig. 2.
Bacterial cell counts in milk (mean log CFU/mL ± s.e.) from animals of the different
experimental groups during a 9 day period after challenge with S. aureus. Immunization was
done with S. aureus bacterins (a) or cell-free components (b). The results obtained in the
control group, experimentally infected, are included. When an animal died from mastitis
within the 9 day post-challenge period, the log CFU/mL recorded at death was fixed and
used thereafter for this animal till the end of the experimental period.
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Fig. 3.
Kaplan-Meier Cumulative Survival Plot of cell-free immunized groups and the non-
immunized control group, after challenge with S. aureus.
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Fig. 4.
Antibody response (O.D., expressed as A405 mean ± standard error, s.e.) in 16 control-group
sheep after challenge with S. aureus, as detected by PNAG ELISA. Each column represents
the daily serum sample (one column per day) obtained during the 9-day post-challenge
period. Animals which did not reach the end of the experimental period and died from
mastitis are indicated with the “†” symbol.
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Table 2
Characteristics of the experimental animal groups and inocula used in the sheep vaccination assay
Group of animals No. of animals
Inoculum
Type
S. aureus isolate / Biofilm phenotype /
CP type Adjuvant
1 8 Bacterin ATCC29213 / strong / CP5 Aluminum hydroxide
2 8 Bacterin C104 / strong / ND* Aluminum hydroxide
3 8 Bacterin ATCC29213 / strong / CP5 Commercial
4 8 Bacterin ATCC29213 / weak/ CP5 Aluminum hydroxide
5 8 Bacterin C104 / weak / ND* Aluminum hydroxide
6 5 PNAG ATCC29213 / weak / CP5 Liposomes and E. coli
7 5 PNAG-containing crude extract ATCC29213 / strong / CP5 + 76 / strong /
CP8
Liposomes
8 5 PNAG ATCC29213 / strong / CP5 Microparticles
9 10 PNAG ATCC29213 / strong / CP5 Liposomes
Control 16 PBS Control None
*
ND: No data on capsular type (it is not CP5, not CP8)
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